{"@context":"https://schema.org","@type":"ScholarlyArticle","headline":"Abstract 5981: CAP70 suppresses the development of triple-negative breast cancer by inhibiting EGFR pathway activation","author":[{"@type":"Person","name":"Junfang Zheng"},{"@type":"Person","name":"Yuanzhen Ma"},{"@type":"Person","name":"Y. Qi"}],"datePublished":"2020","isPartOf":{"@type":"Periodical","name":"Cancer Research"},"identifier":"https://doi.org/10.1158/1538-7445.am2020-5981","description":"Abstract\n Background: Among all major subtypes of breast cancer, triple-negative breast cancer (TNBC) carries the worst prognosis for the patients. The poor clinical outcome of TNBC is further exacerbated by the lack of effective targeted therapies. Therefore, the identification of functional molecular targets for TNBC therapy is urgently needed. The goal of this study was to determine the role of CFTR-associated protein of 70 kDa (CAP70, also called PDZK1) in the development of TNBC and assess its value as a target for TNBC therapy.\n Methods: Bioinformatics analysis and immunohistochemistry were performed to determine the expression of CAP70 in TNBC. The functions of CAP70 were demonstrated in a series of in vitro and in vivo experiments. GST Pull-down, mass spectrometry, co-immunoprecipitation, bioinformatics analysis, pharmacologic treatment, and western blotting were performed to elucidate the potential mechanisms of CAP70 activities.\n Results: CAP70 was specifically downregulated in TNBC tissues and was related to tumor stage, lymph node metastasis, and patient survival. Functional assays showed that CAP70 suppressed TNBC carcinogenesis, progression, and metastasis by inhibiting EGFR signaling. Moreover, inhibition of EGFR signaling by CAP70 enhanced the sensitivity of TNBC to EGFR inhibitor erlotinib.\n Conclusions: CAP70 suppresses TNBC development and enhances its sensitivity to erlotinib by inhibiting EGFR signaling. CAP70 is a significant prognostic factor of TNBC and a potential molecular therapeutic target for the treatment of this subtype of breast cancer.\n Citation Format: Junfang Zheng, Yuanzhen Ma, Yijun Qi. CAP70 suppresses the development of triple-negative breast cancer by inhibiting EGFR pathway activation [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 5981.","url":"https://innscience.ca/es/community/literature/5fa227a0-0bd5-4bb3-9443-af53a8a660dd"}